JP2016501884A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016501884A5 JP2016501884A5 JP2015545886A JP2015545886A JP2016501884A5 JP 2016501884 A5 JP2016501884 A5 JP 2016501884A5 JP 2015545886 A JP2015545886 A JP 2015545886A JP 2015545886 A JP2015545886 A JP 2015545886A JP 2016501884 A5 JP2016501884 A5 JP 2016501884A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- rigosatib
- composition according
- formula
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 239000002246 antineoplastic agent Substances 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 4
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 3
- 108010074604 Epoetin Alfa Proteins 0.000 claims 3
- 229960002756 azacitidine Drugs 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 229960003603 decitabine Drugs 0.000 claims 3
- 239000003968 dna methyltransferase inhibitor Substances 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 229940126190 DNA methyltransferase inhibitor Drugs 0.000 claims 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 108010002601 epoetin beta Proteins 0.000 claims 2
- 229960004579 epoetin beta Drugs 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims 2
- 101710164820 Flotillin-2 Proteins 0.000 claims 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229930013930 alkaloid Natural products 0.000 claims 1
- 150000003797 alkaloid derivatives Chemical class 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 210000002798 bone marrow cell Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960003388 epoetin alfa Drugs 0.000 claims 1
- 229940089118 epogen Drugs 0.000 claims 1
- 230000010437 erythropoiesis Effects 0.000 claims 1
- 229940125367 erythropoiesis stimulating agent Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 229960004942 lenalidomide Drugs 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 229940029359 procrit Drugs 0.000 claims 1
- 239000008213 purified water Substances 0.000 claims 1
- OWBFCJROIKNMGD-BQYQJAHWSA-N rigosertib Chemical compound COC1=CC(OC)=CC(OC)=C1\C=C\S(=O)(=O)CC1=CC=C(OC)C(NCC(O)=O)=C1 OWBFCJROIKNMGD-BQYQJAHWSA-N 0.000 claims 1
- 229950006764 rigosertib Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261734933P | 2012-12-07 | 2012-12-07 | |
| US61/734,933 | 2012-12-07 | ||
| US201361826973P | 2013-05-23 | 2013-05-23 | |
| US61/826,973 | 2013-05-23 | ||
| PCT/US2013/073667 WO2014089483A1 (en) | 2012-12-07 | 2013-12-06 | Methods and compositions for treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501884A JP2016501884A (ja) | 2016-01-21 |
| JP2016501884A5 true JP2016501884A5 (enExample) | 2017-01-12 |
| JP6462582B2 JP6462582B2 (ja) | 2019-01-30 |
Family
ID=50884042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545886A Active JP6462582B2 (ja) | 2012-12-07 | 2013-12-06 | がんの治療のための方法および組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10576050B2 (enExample) |
| EP (1) | EP2928456B1 (enExample) |
| JP (1) | JP6462582B2 (enExample) |
| ES (1) | ES2864681T3 (enExample) |
| WO (1) | WO2014089483A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3004387A4 (en) * | 2013-05-31 | 2017-04-12 | Onconova Therapeutics, Inc. | Methods and compositions for predicting therapeutic efficacy of kinase inhibitors in patients with myelodysplastic syndrome or related disorders |
| AR109503A1 (es) * | 2017-04-13 | 2018-12-19 | Onconova Therapeutics Inc | Composición farmacéutica que comprende (e)-2,4,6-trimetoxiestiril-3-[(carboximetil)amino]-4-metoxibencilsulfona, forma de dosificación oral y método de tratamiento |
| US11382877B2 (en) | 2017-04-13 | 2022-07-12 | Onconova Therapeutics, Inc. | Formulation of (E)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailability |
| US12156856B2 (en) | 2017-04-13 | 2024-12-03 | Traws Pharma, Inc. | Formulation of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone with enhanced stability and bioavailability |
| CA3228644A1 (en) * | 2021-08-12 | 2023-02-16 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE284386T1 (de) | 1997-10-03 | 2004-12-15 | Univ Temple | Styrolsulfone als antikrebsmittel |
| US6548553B2 (en) | 1997-10-03 | 2003-04-15 | Temple University-Of The Commonwealth System Of Higher Education | Styryl sulfone anticancer agents |
| US6201154B1 (en) | 1999-03-31 | 2001-03-13 | Temple University-Of The Commonwealth Of Higher Education | Z-styryl sulfone anticancer agents |
| US6762207B1 (en) | 1999-04-02 | 2004-07-13 | Temple University - Of The Commonwealth System Of Higher Education | (E)-styryl sulfone anticancer agents |
| US6541475B2 (en) | 2000-04-14 | 2003-04-01 | Temple University - Of The Commonwealth System Of Higher Education | α, β-unsaturated sulfones for treating proliferative disorders |
| US6486210B2 (en) | 2000-04-14 | 2002-11-26 | Temple University—Of the Commonwealth System of Higher Education | Substituted styryl benzylsulfones for treating proliferative disorders |
| CA2424884C (en) | 2000-10-05 | 2009-12-15 | E. Premkumar Reddy | Substituted (e)-styryl benzylsulfones for treating proliferative disorders |
| WO2002067913A1 (en) | 2001-02-27 | 2002-09-06 | Temple University-Of The Commonwealth System Of Higher Education | (z)-styrylbenzylsulfones and pharmaceutical uses thereof |
| NZ535232A (en) | 2002-02-28 | 2007-05-31 | Univ Temple | Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders |
| AU2005265412B2 (en) | 2004-07-19 | 2010-09-02 | Onconova Therapeutics, Inc. | Formulations for parenteral administration of (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones |
| CA2675374C (en) | 2007-01-16 | 2014-03-04 | Onconova Therapeutics, Inc. | Formulations for parenteral administration of amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones |
| AU2008354754B2 (en) * | 2008-04-17 | 2014-09-11 | The Johns Hopkins University | On01910. Na enhances chemotherapeutic agent activity in drug-resistant tumors |
| CN102438588B (zh) * | 2009-03-23 | 2015-04-01 | 埃姆比特生物科学公司 | 使用联合治疗法治疗疾病的方法 |
| US20140120083A1 (en) * | 2012-11-01 | 2014-05-01 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
-
2013
- 2013-12-06 ES ES13860034T patent/ES2864681T3/es active Active
- 2013-12-06 JP JP2015545886A patent/JP6462582B2/ja active Active
- 2013-12-06 WO PCT/US2013/073667 patent/WO2014089483A1/en not_active Ceased
- 2013-12-06 US US14/649,759 patent/US10576050B2/en active Active
- 2013-12-06 EP EP13860034.1A patent/EP2928456B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102421429B (zh) | 癌症治疗用选择性ep4受体拮抗物质 | |
| US20170232017A1 (en) | Treatment of cancer | |
| RU2306933C2 (ru) | Улучшенная схема применения противоопухолевого соединения в терапии рака | |
| JP2020055884A (ja) | がんのためのグルフォスファミド組み合わせ療法 | |
| JP2011503063A5 (enExample) | ||
| CN1349406A (zh) | 含吗啉蒽环类化生物和抗癌剂的联合制剂 | |
| RU2020134307A (ru) | Режимы дозирования мелфлуфена для раковых заболеваний | |
| CA3166741A1 (en) | Combination therapy for treating cancer | |
| US6596320B1 (en) | Method for treating cancer having greater efficacy and reduced adverse effects | |
| JP2009292837A (ja) | より効能が大きく副作用の少ない癌治療方法 | |
| EP3609878B1 (en) | Compounds, composition and uses thereof for treating cancer | |
| US7863255B2 (en) | Methods of administering antitumor agent comprising deoxycytidine derivative | |
| JP2011514355A5 (enExample) | ||
| JP2011514356A5 (enExample) | ||
| EP2826482A1 (en) | Novel antitumor agent comprising combination of three agents | |
| US11179349B2 (en) | Use of tumor gene methylation regulator and anti-tumor drugs | |
| WO2020139300A2 (en) | A combination comprising granulocyte colony stimulating factor | |
| CN102083436A (zh) | 抗肿瘤组合物和方法 | |
| JP2016017059A (ja) | 抗腫瘍性プロドラッグを含む組成物 | |
| WO2022266384A1 (en) | Methods for treating cancer | |
| KR20220082862A (ko) | 혈액 악성 종양을 치료하기 위한 병용 요법 | |
| HK1225604A (en) | Selective ep4 receptor agonistic substance for treatment of cancer | |
| HK1225604A1 (en) | Selective ep4 receptor agonistic substance for treatment of cancer | |
| HK1167090B (en) | Selective ep4 receptor agonistic substance for treatment of cancer | |
| ES2594499A1 (es) | Complejos de Rutenio para el tratamiento del cáncer |